Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial

OBJECTIVES: Open-labelled clinical trials suggested that low-dose IL-2 might be effective in treatment of systemic lupus erythematosus (SLE). A double-blind and placebo-controlled trial is required to formally evaluate the safety and efficacy of low-dose IL-2 therapy. METHODS: A randomised, double-b...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Jing, Zhang, Ruijun, Shao, Miao, Zhao, Xiaozhen, Miao, Miao, Chen, Jiali, Liu, Jiajia, Zhang, Xiaoying, Zhang, Xia, Jin, Yuebo, Wang, Yu, Zhang, Shilei, Zhu, Lei, Jacob, Alexander, Jia, Rulin, You, Xujie, Li, Xue, Li, Chun, Zhou, Yunshan, Yang, Yue, Ye, Hua, Liu, Yanying, Su, Yin, Shen, Nan, Alexander, Jessy, Guo, Jianping, Ambrus, Julian, Lin, Xin, Yu, Di, Sun, Xiaolin, Li, Zhanguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937406/
https://www.ncbi.nlm.nih.gov/pubmed/31537547
http://dx.doi.org/10.1136/annrheumdis-2019-215396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937406/
https://www.ncbi.nlm.nih.gov/pubmed/31537547
http://dx.doi.org/10.1136/annrheumdis-2019-215396

Ejemplares similares